Our data suggest that either the combined inhibition of different targetable proteins associated with mitosis, including UBE2C, PLK1, and BIRC5, or the combination of volasertib with bempedoic acid may significantly inhibit the mRNA expression of MBTPS2, resulting in metabolic disorders, inducing the apoptosis of tumor cells, and contributing to the inhibition of SREBF1 expression. Here, UBE2C is linked to metabolic disease.